This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smallridge, R. C. Articles by Solomon, B. L. Search for Related Content PubMed PubMed Citation Articles by Smallridge, R. C. Articles by Solomon, B. L.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, Sep 1997, 583-586, Vol 4, No. 5
Copyright © 1997 by the American Society for Microbiology. All rights reserved.

Soluble interleukin-2 receptor is a thyroid hormone-dependent early- response marker in the treatment of thyrotoxicosis

RC Smallridge, GC Tsokos, KD Burman, L Porter, T Cranston, PP Sfikakis and BL Solomon
Endocrinology Division, Mayo Clinic Jacksonville, Florida 32224, USA.

Thyrotoxic patients exhibit increased levels of immune activation molecules (soluble interleukin-2 receptor [sIL-2R], intercellular adhesion molecule-1 [ICAM-1], and endothelial-leukocyte adhesion molecule-1 [ELAM-1]) in serum, although the clinical significance of these measurements remains unclear. In a randomized 4-week study, we have recently shown that in the treatment of hyperthyroidism, the combination of cholestyramine and methimazole (MMI) resulted in faster lowering of serum thyroid-hormone levels than did MMI alone. Stored serial serum samples from patients participating in this randomized treatment trial were analyzed for sIL-2R, soluble ICAM-1 (sICAM-1), and soluble ELAM-1 (sELAM-1). The levels of all three molecules were elevated in patients with hyperthyroidism. Although the levels of sICAM- 1 and sELAM-1 remained elevated through the 4-week follow-up period in both groups of patients, the sIL-2R levels (normal levels, 1.0 to 4.2 ng/ml) decreased significantly in the 10 patients who received cholestyramine in addition to MMI (week 0, 14.2 +/- 1.5 ng/ml; week 2, 10.8 +/- 1.2 ng/ml; week 4, 8.9 +/- 1.5 ng/ml). In eight patients who received MMI alone, sIL-2R decreased less rapidly (week 0, 12.3 +/- 1.4 ng/ml; week 2, 12.3 +/- 1.3 ng/ml; week 4, 10.9 +/- 1.3 ng/ml). sICAM-1 and sELAM-1 were elevated at baseline but did not decrease during therapy. In the former group, free thyroxine and free triiodothyronine decreased faster. These data show that levels of sIL-2R in serum, but not those of sICAM-1 and sELAM-1, may be of clinical use in the early follow-up evaluation of medically treated patients.

This article has been cited by other articles:

• Feldkamp, J., Pascher, E., Schott, M., Goretzki, P., Seissler, J., Scherbaum, W. A. (2001). Soluble Fas Is Increased in Hyperthyroidism Independent of the Underlying Thyroid Disease. J. Clin. Endocrinol. Metab. 86: 4250-4253 [Abstract] [Full Text]